Do Kim
Stock Analyst at Piper Sandler
(2.00)
# 3,098
Out of 5,115 analysts
92
Total ratings
44.93%
Success rate
3.01%
Average return
Main Sectors:
Stocks Rated by Do Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $62 → $63 | $82.67 | -23.79% | 18 | Feb 22, 2024 | |
| TVTX Travere Therapeutics | Maintains: Overweight | $42 → $46 | $31.09 | +47.96% | 6 | Feb 21, 2023 | |
| VRTX Vertex Pharmaceuticals | Maintains: Neutral | $296 | $469.90 | -37.01% | 13 | Feb 8, 2023 | |
| GILD Gilead Sciences | Maintains: Overweight | $111 → $112 | $141.95 | -21.10% | 7 | Feb 3, 2023 | |
| SDGR Schrödinger | Maintains: Overweight | $86 → $87 | $13.97 | +522.76% | 5 | Jan 19, 2023 | |
| CDXS Codexis | Maintains: Overweight | $22 → $23 | $1.24 | +1,754.84% | 2 | Jan 19, 2023 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $10 → $20 | $34.86 | -42.63% | 3 | Aug 17, 2022 | |
| REPL Replimune Group | Maintains: Overweight | $44 → $43 | $7.03 | +511.66% | 2 | Aug 16, 2022 | |
| EXEL Exelixis | Maintains: Overweight | $30 → $32 | $41.36 | -22.63% | 1 | Jul 26, 2022 | |
| ABCL AbCellera Biologics | Maintains: Overweight | $21 → $22 | $3.62 | +507.73% | 4 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $19 | $44.34 | -57.15% | 3 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $5.24 | +205.34% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $185 | $338.06 | -45.28% | 14 | Jan 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $4.07 | +22,013.02% | 1 | Dec 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $35 | $71.71 | -51.19% | 11 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $20 | $1.19 | +1,580.67% | 1 | Mar 6, 2018 |
Ionis Pharmaceuticals
Feb 22, 2024
Maintains: Overweight
Price Target: $62 → $63
Current: $82.67
Upside: -23.79%
Travere Therapeutics
Feb 21, 2023
Maintains: Overweight
Price Target: $42 → $46
Current: $31.09
Upside: +47.96%
Vertex Pharmaceuticals
Feb 8, 2023
Maintains: Neutral
Price Target: $296
Current: $469.90
Upside: -37.01%
Gilead Sciences
Feb 3, 2023
Maintains: Overweight
Price Target: $111 → $112
Current: $141.95
Upside: -21.10%
Schrödinger
Jan 19, 2023
Maintains: Overweight
Price Target: $86 → $87
Current: $13.97
Upside: +522.76%
Codexis
Jan 19, 2023
Maintains: Overweight
Price Target: $22 → $23
Current: $1.24
Upside: +1,754.84%
Rigel Pharmaceuticals
Aug 17, 2022
Maintains: Neutral
Price Target: $10 → $20
Current: $34.86
Upside: -42.63%
Replimune Group
Aug 16, 2022
Maintains: Overweight
Price Target: $44 → $43
Current: $7.03
Upside: +511.66%
Exelixis
Jul 26, 2022
Maintains: Overweight
Price Target: $30 → $32
Current: $41.36
Upside: -22.63%
AbCellera Biologics
Jul 26, 2022
Maintains: Overweight
Price Target: $21 → $22
Current: $3.62
Upside: +507.73%
Jun 23, 2022
Maintains: Overweight
Price Target: $28 → $19
Current: $44.34
Upside: -57.15%
Mar 8, 2021
Initiates: Outperform
Price Target: $16
Current: $5.24
Upside: +205.34%
Jan 25, 2021
Downgrades: Market Perform
Price Target: $185
Current: $338.06
Upside: -45.28%
Dec 18, 2020
Initiates: Outperform
Price Target: $900
Current: $4.07
Upside: +22,013.02%
May 12, 2020
Maintains: Outperform
Price Target: $27 → $35
Current: $71.71
Upside: -51.19%
Mar 6, 2018
Maintains: Outperform
Price Target: $7 → $20
Current: $1.19
Upside: +1,580.67%